NCT04472494View on ClinicalTrials.gov

Study of Abatacept in the Treatment of Hospitalized COVID-19 Participants With Respiratory Compromise

PHASE2TerminatedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

October 14, 2020

Primary Completion Date

August 12, 2021

Study Completion Date

September 13, 2021

Conditions
COVID-19SARS-CoV-2
Interventions
BIOLOGICAL

Abatacept

Specified dose on specified days

OTHER

Placebo

Specified dose on specified days

Trial Locations (10)

33012

Alternative Research Associates, Llc, Hialeah

Alternative Research Associates, Hialeah

40202

Norton Infectious Disease Institute, Louisville

75203

Methodist Health System Clinical Research Institute (MHSCRI), Dallas

02115

Boston Childrens Hospital, Boston

02215

Local Institution - 0002, Boston

07960

Atlantic Health System, Morristown

00968

CardioPulmonary Research, Guaynabo

00780

Ponce Medical School Foundation, Ponce

00927

Fundacion de Investigacion de Diego, San Juan

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT04472494 - Study of Abatacept in the Treatment of Hospitalized COVID-19 Participants With Respiratory Compromise | Biotech Hunter | Biotech Hunter